# TRITONS: HCP commentary report

> 38 verified statements (28 from clinicians verified by NPI or staff page) from 7 commentary sources · 6 findings · updated Oct 30, 2026

## Report

- Trial: Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)
- NCT ID: NCT06587490
- Registry: https://clinicaltrials.gov/study/NCT06587490
- Sponsor: University of California, San Diego
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: none (the trial tests no drug)
- Indication: oligometastatic cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-30
- Last checked: 2026-10-30
- Release hash: e49dc75a9fb02675f7a3095743ed081a60fb84a0aab74f3051fd05eb7c090258

## Counts

- HCP commentary sources screened: 22
- Sources cited by verified statements: 8
- Verified statements: 38
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 28
- Findings: 6
- Named people in screened sources (unnamed speakers and accounts not counted): 12
- Voices cited: 12
- Cited voices identity-verified: 12
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

TRITONS asks whether adding stereotactic ablative radiotherapy to standard care improves outcomes in oligometastatic solid cancers. One X poster contests technical ablatability as a biological definition of oligometastasis. A speaker, described in the source as a principal investigator of TRITONS, expresses optimism about ablation alongside calls for randomized evidence; an X poster relays uncertainty about safe treatment extent. Which patients benefit, and how disease control balances against treatment harm, remain open questions.

## Open Medical Affairs question

Which baseline biology, disease pace, systemic-treatment context and imaging approach identify patients likely to gain net benefit from adding SABR?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Technical ablatability is not an agreed biological definition of oligometastasis
- F2. Prostate progression patterns support a proposed mechanism, not proof of added MDT benefit
- F3. Prostate response assessment is a specific methodological concern
- F4. The upper treatment burden and safe extent of ablation remain open questions
- F5. Interest in biomarker selection is practical, but the discussed test has a colorectal-surgery scope
- F6. Optimism is accompanied by calls for randomization, enrollment and benefit-based selection

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 12 | 13 | 2 | 4 | recorded | 2 |
| F2 | 8 | 9 | 1 | 6 | recorded | 2 |
| F3 | 3 | 3 | 2 | 3 | none recorded | 2 |
| F4 | 6 | 8 | 4 | 4 | recorded | 3 |
| F5 | 6 | 7 | 1 | 3 | none recorded | 3 |
| F6 | 7 | 7 | 5 | 4 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 0 | 1 | 2 | 2 | 15 | 2 | 1 post or article, 1 registry | yes |
| F2 | 4 | 2 | 0 | 1 | 1 | 9 | 0 | 1 post or article | yes |
| F3 | 2 | 1 | 0 | 0 | 0 | 3 | 0 | 2 posts and articles | yes |
| F4 | 2 | 1 | 0 | 0 | 3 | 7 | 3 | 3 posts and articles, 1 registry | yes |
| F5 | 3 | 1 | 0 | 0 | 2 | 8 | 1 | 1 post or article | yes |
| F6 | 4 | 1 | 0 | 0 | 2 | 7 | 0 | 4 posts and articles, 1 registry | yes |

### Trial dimensions

- Primary endpoint: Progression-Free Survival (PFS): no finding draws on it directly
- Secondary endpoint: All-grade and grade ≥3 toxicity: no finding draws on it directly
- Population and setting: F1 (8 shared claims), F4 (1 shared claims), F6 (2 shared claims)
- The comparison: F1 (1 shared claims), F2 (3 shared claims), F4 (2 shared claims), F6 (1 shared claims)
- Safety and tolerability: F4 (2 shared claims), F6 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F5 (1 shared claims), F6 (5 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F4. The upper treatment burden and safe extent of ablation remain open questions

An X thread reporting a talk addresses how extensively metastatic sites can be treated safely in the oligometastatic setting studied by TRITONS.

The safety statement is relayed from a talk rather than a direct account by its presenter.

Interpretations of a separate trial elsewhere in this finding are not TRITONS results.

The sources reviewed for this edition provide neither TRITONS toxicity rates nor an established optimal fractionation schedule.

Source: X thread, 2026-04-16.

### F3. Prostate response assessment is a specific methodological concern

An X post raises the question of which imaging response criteria to use for prostate metastases in TRITONS.

The principal-investigator involvement is described by the source, not independently confirmed.

The comments concern prostate cancer and should not be generalized to every tumor type in TRITONS.

The sources reviewed for this edition do not describe a validated replacement assessment framework or document a change to TRITONS assessment methods.

Source: X thread, 2025-10-06.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 38 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 8 | Counts free |
| Speaker attribution for cited voices | 12 | Paid |

## Trial aspects

10 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression-Free Survival (PFS) | no commentary found | 0 | 0 |
| Secondary endpoint: All-grade and grade ≥3 toxicity | no commentary found | 0 | 0 |
| Population and setting | discussed | 11 | 4 |
| The comparison | discussed | 7 | 4 |
| Safety and tolerability | discussed | 2 | 2 |
| Design and conduct | discussed | 7 | 5 |
| Biological spectrum, disease pace and the interpretation of ablation trials | discussed | 11 | 1 |
| Prostate imaging, lesion definition and response assessment | discussed | 3 | 2 |
| De novo oligometastatic hormone-sensitive prostate cancer: progression-pattern rationale for MDT | discussed | 8 | 1 |
| Colorectal-surgery biomarker scope, access and disclosure | discussed | 6 | 1 |
| Single-fraction SBRT as an optimization question | discussed | 1 | 1 |
| Randomized secondary analyses and net clinical benefit | discussed | 2 | 1 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 15 | 7 |
| Bluesky threads | 7 | 0 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2024-09-12 to 2026-10-23
- Cited window: 2025-07-03 to 2026-10-23
- Retrieved: 2026-10-30

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Total RadIoTherapy of Oligometastatic caNcerS (TRITONS)
- Registry: NCT06587490 (https://clinicaltrials.gov/study/NCT06587490)
- Study IDs: 810616
- Sponsor: University of California, San Diego
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 300 (estimated)
- Start: 2024-11-12 (actual)
- Primary completion: 2033-11 (estimated)
- Primary endpoint: Progression-Free Survival (PFS) (2 years)
- Intervention: stereotactic ablative radiotherapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- The source search did not run to completion, so some matching discussion may be missing.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are selected public discussions, not a representative survey. Some relevant passages were not fully assessed, and unnamed or differently worded references to the trial may be missing.
- No TRITONS efficacy or toxicity results are provided. The October 2026 publication discussion concerns a protocol announcement and linked article information, not a results report or a complete protocol assessment.
- Several discussions concern separate settings, including de novo oligometastatic hormone-sensitive prostate cancer, oligoprogressive disease and colorectal-cancer surgery. Their interpretations cannot be treated as TRITONS outcomes or validated selection rules for its entire population.
- A speaker's statements about the talk are relays rather than a direct transcript of its presenter. Another speaker's principal-investigator involvement is described by the source and should not be treated as an independently established role or an external appraisal.
- Reposts and relays do not establish additional independent HCP agreement. The nature of a speaker's disclosed interest in the prognostic test remains unclear.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-30: current edition

Last checked for new commentary 2026-10-30. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (38 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (12 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/tritons-nct06587490
- Agents: POST https://www.erudio.com/api/orders with {"report": "tritons-nct06587490", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=tritons-06587490

## Cite

Erudio Health. TRITONS (NCT06587490): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 30, 2026. https://www.erudio.com/reports/tritons-nct06587490

## Machine access

- JSON: https://www.erudio.com/reports/tritons-nct06587490.json
- Markdown: https://www.erudio.com/reports/tritons-nct06587490.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "tritons-06587490"}`